Bellevue Medtech & Services (CH)
Medtech & Services is an investment in 10% of global gross domestic product: Healthcare sector excluding drugs
Bottom line: above-average and steady growth compared to the broad market
Focusing on profitable, liquid mid and large cap companies with an established product portfolio
Please find a more detailed description of share classes here.
The Fund invests worldwide in companies active in the medical technology and healthcare services sector. Stock selection is based on fundamental company analysis, focusing in particular on the medical benefits and the potential savings for the healthcare system as well as the expected market potential of a company’s products and services.
Indexed performance (as at: 03.12.2021)
NAV: CHF 3'918.83 (02.12.2021)
Rolling performance (02.12.2021)
|02.12.2020 - 02.12.2021||19.59%||17.54%|
|02.12.2019 - 02.12.2020||5.76%||8.15%|
|02.12.2018 - 02.12.2019||7.31%||11.05%|
|02.12.2017 - 02.12.2018||28.63%||17.36%|
Annualized performance (02.12.2021)
|Since Inception p.a.||12.74%||11.53%|
Cumulative performance (02.12.2021)
Facts & Key figures
The Fund invests worldwide in companies active in the medical technology and healthcare services sector. Aim is to provide investors an attractive Healthcare Fund solution by investing in the entire healthcare universe with the exclusion of drug makers. Experienced sector specialists focus on profitable, liquid mid- and large-cap companies with an established product portfolio as well as fast growing small-cap companies with leading-edge technology offering. Stock selection is based on fundamental company analysis, focusing in particular on the medical benefits and the potential savings for the healthcare system as well as the expected market potential of a company’s products and services. A global network of experts spanning scientific and industrial fields supports the Management Team in forming opinions and making investment decisions. The selection of the portfolio companies is entirely bottom-up, independent of benchmark weightings.Show moreShow less
Investment suitability & Risk
|Investment Manager||Bellevue Asset Management AG|
|Fund Administrator||Swisscanto Fondsleitung AG|
|Auditor||Ernst & Young AG|
|Year end closing||30. Sep|
|NAV Calculation||Daily "Forward Pricing"|
|Cut of time||15:00 CET|
|Subscription Fee (max.)||2.50%|
|Performance Fee||10.00% (with High Water Mark)|
Key data (30.11.2021, base currency CHF)
|No. of positions||45|
Top 10 positions
Breakdown by sector
Opportunities & Risks
- Digitalization of the healthcare sector is boosting medtech companies’ growth and earnings.
- Focusing on profitable, liquid mid and large-cap companies with an established product portfolio as well as on rapidly growing small-cap businesses delivering cutting-edge technology.
- Managed care profits from the privatization of the health insurance sector and lower treatment costs.
- Minimally invasive techniques gaining ground – shorter treatment times reduce healthcare costs.
- Bellevue - Healthcare pioneer since 1993 and today one of the biggest independent investors in the sector in Europe.
- Equities are subject to price fluctuations and so are also exposed to the risk of price losses.
- The fund invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
- The fund may invest in financial instruments that might have a relatively low level of liquidity, which can in turn affect the fund’s liquidity.
- Investing in emerging markets entails the additional risk of political and social instability.
- Increased opportunities through possible derivative transactions go hand in hand with increased risk of loss
Review / Outlook
October was a very pleasing month for the Bellevue Medtech & Services (CH) Fund (+6.3%). The fund sailed past its benchmark (+3.3%), the broader healthcare sector (+2.3%) and the overall stock market (+3.7%). Healthcare services contributed 4.4% to the fund's monthly performance, medtech stocks 1.9%.
US health insurers Humana (+16.8%), UnitedHealth (+15.7%), Anthem (+14.6%) and Centene (+12.2%) made a big contribution to the fund's positive performance in both absolute and relative terms. Insured costs for COVID-19 treatments during the “Delta wave” of new infections were more than offset by a significant drop in non-coronavirus-related health costs, which allowed health insurers to beat consensus profit estimates for the third quarter by a wide margin. Health insurers also provided some initial positive guidance for 2022 with their earnings reports and investors were pleased with what they heard. In October, 13 US senators – including 8 from the Democratic party – vehemently opposed any cuts in payments to the Medicare Advantage program, the US health insurance plan for the elderly. This is a clear political signal that strengthens the Medicare Advantage program, in which 44% of all US citizens age 65 and older are now enrolled.
Shares of the two digital health companies Inspire Medical (+13.6%) and M3 (-19.5%) moved in different directions. The Japanese company M3 hurt the fund's monthly performance. Its weakness had more to do with the general market environment in Japan than with the company’s fundamentals.
The positive contribution of medtech companies to the fund's performance is mostly attributable to the ongoing third-quarter reporting season. Dexcom (+11.9%), Intuitive Surgical (+7.0%), Abbott (+7.5%) and Edwards Lifesciences (+3.9%) had no problems beating investors’ low expectations. The wave of Delta infections in July and August had a slightly negative impact on corporate earnings. Medical procedures showed some sequential weakness but were still at higher levels compared to the third quarter of 2019. All medical technology companies also reported a steady recovery in the number of interventions in September and October and this positive news confirms our investment case. Despite investor concerns about a staffing crisis at hospitals and supply chain disruptions (e.g. shortage of electronic components), these have not proven to be material factors and most companies have so far managed them very well. Boston Scientific (-2.4%) was marked down because the third-quarter sales growth figures it announced on the occasion of its investor day failed to beat its previously reduced guidance.
The life sciences tools company Thermo Fisher (+8.8%) beat consensus expectations for the third quarter and raised its full-year guidance for 2021 and 2022. All performance figures in CHF.
Vaccination rates in key medtech & services markets (North America, Europe and Japan) were slightly higher at the end of October. Between 69% and 81% of the population in major Western European countries have already received at least one dose of a coronavirus vaccine. In the US, 66% of the total population is vaccinated and in Japan 78%.
Widespread availability COVID-19 vaccines, a growing number of people who have recovered from coronavirus and newly available drugs that reduce the need for emergency or hospital care are important prerequisites for an upturn in elective interventions during the final quarter of 2021 and into the coming year. Regions with low vaccination rates could experience a renewed surge in hospital admissions during the next few months.
In the healthcare services segment, we believe US health insurers offer the most upside potential. Major value drivers are progressive privatization (Medicare Advantage, Medicaid), a larger pool of insured persons (commercial), the vertical integration of services providers, and efficiency gains (digitalization reduces administrative costs). Hospitals stand to benefit from the normalization of elective procedures.
We see substantial upside potential in medtech stocks thanks to their strong innovation, which is particularly evident in the latest products for diabetes therapy, minimally invasive heart valve repair and replacement procedures, and surgical robots.
Past performance is not a reliable indicator of future results and can be misleading. As the sub-fund is denominated in a currency that may differ than an investor’s base currency, changes in the rate of exchange may have an adverse effect on prices and incomes. Performance is shown net of fees and expenses for the relevant share class over the reference period. All performance figures reflect the reinvestment of dividends and do not take into account the commissions and costs incurred on the issue and redemption of shares, if any. Individual costs are not taken into account and would have a negative impact on the performance. With an investment amount of EUR 1,000 over an investment period of five years, the investment result in the first year would be reduced by the front-end load of up to EUR 50 (5%) as well as by additional individual custody charges. In subsequent years, the investment result would also be reduced by the individual custody account costs incurred. The reference benchmark of this class is used for performance comparison purposes only (dividend reinvested). No benchmark is directly identical to a sub-fund, thus the performance of a benchmark is not a reliable indicator of future performance of the sub-fund it is compared to. There can be no assurance that a return will be achieved or that a substantial loss of capital will not be incurred. All figures in base currency in %, calculated by the total return / BVI method.Show moreShow less